Transcranial Histotripsy Parameter Study in Primary and Metastatic Murine Brain Tumor Models
Overview
Pharmacology
Authors
Affiliations
Objective: This study investigated the effect of various histotripsy dosages on tumor cell kill and associated bleeding in two murine brain tumor models (glioma [Gl261] and lung metastasis [LL/2-Luc2]).
Methods And Materials: GL261 or LL/2-Luc2 cells were cultured and implanted into the brains of C57BL/6 mice. Histotripsy (1-cycle pulses, 5 Hz PRF, 30 MPa-P) was performed using a 1 MHz transducer for five different dosages for each cell line: 5, 20 or 200 pulses per location (PPL) at a single treatment point, or 5 or 10-20 PPL at multiple treatment points. MRI, bioluminescence imaging and histology were used to assess tumor ablation and treatment effects within 4-6 h post-treatment.
Results: All treatment groups resulted in a reduction of BLI intensity for the LL/2-Luc2 tumors, with significant signal reductions for the multi-point groups. The average pre-/post-treatment BLI flux (photons/s, ×10) for the different treatment groups were: 4.39/2.19 (5 PPL single-point), 5.49/1.80 (20 PPL single-point), 3.86/1.73 (200 PPL single-point), 2.44/1.11 (5 PPL multi-point) and 5.85/0.80 (10 PPL multi-point). MRI and H&E staining showed increased tumor damage and hemorrhagic effects with increasing histotripsy dose for both GL261 and LL/2-Luc2 tumors, but the increase in tumor damage was diminished beyond 10-20 PPL for single-point treatments and outweighed by increased hemorrhage. In general, hemorrhage was confined to be within 1 mm of the treatment boundary for all groups.
Conclusions: Our results suggest that a lower number of histotripsy pulses at fewer focal locations can achieve substantial tumor kill while minimizing hemorrhage.
Cwiklinska A, Przewodowska D, Koziorowski D, Szlufik S Cancers (Basel). 2025; 16(24.
PMID: 39766134 PMC: 11674718. DOI: 10.3390/cancers16244235.
A pre-clinical MRI-guided all-in-one focused ultrasound system for murine brain studies.
Kaovasia T, Duclos S, Gupta D, Kalayeh K, Fabiilli M, Noll D Sci Rep. 2025; 15(1):144.
PMID: 39747938 PMC: 11696467. DOI: 10.1038/s41598-024-84078-9.
Advances in Tumor Management: Harnessing the Potential of Histotripsy.
Verma Y, Perera Molligoda Arachchige A Radiol Imaging Cancer. 2024; 6(3):e230159.
PMID: 38639585 PMC: 11148838. DOI: 10.1148/rycan.230159.
Duclos S, Choi S, Andjelkovic A, Chaudhary N, Camelo-Piragua S, Pandey A Ultrasound Med Biol. 2024; 50(5):639-646.
PMID: 38302370 PMC: 11894761. DOI: 10.1016/j.ultrasmedbio.2023.12.014.
Insights from preclinical cancer studies with histotripsy.
Worlikar T, Hall T, Zhang M, Mendiratta-Lala M, Green M, Cho C Int J Hyperthermia. 2024; 41(1):2297650.
PMID: 38214171 PMC: 11102041. DOI: 10.1080/02656736.2023.2297650.